NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY Russian patent published in 2016 - IPC C07D495/04 A61K31/519 A61K31/5377 A61P35/00 

FIELD: chemistry.

SUBSTANCE: present invention relates to a novel fused pyrimidine derivative of formula (I) or a pharmaceutically acceptable salt thereof, having Bruton's tyrosine kinase inhibitory activity (ECT). Compounds can be used for preparing a drug for preventing or treating Bruton's tyrosine kinase mediated cancers and tumours, such as leukaemia, lymphoma, B-cell lymphoma, T-cell lymphoma, myeloma, acute lymphoid leukaemia (ALL), chronic lymphoid leukaemia (CLL), etc; inflammatory diseases, such as arthritis, rheumatoid arthritis, spondyloarthropathy, gouty arthritis, osteoarthritis, Still's disease, other arthritic conditions, lupus, etc; autoimmune diseases and immunologically mediated diseases, including Sjorgen's syndrome, autoimmune thyroiditis, hives, multiple sclerosis, sclerodermatitis, rejection of transplanted organs, heterotransplantation, idiopathic thrombocytopenic purpura (ITP), Parkinson's disease, Alzheimer's disease, associated with diabetes disease, pelvic inflammation, allergic rhinitis, allergic bronchitis, Hodgkin disease, non-Hodgkins lymphoma, multiple myeloma, myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), diffuse large B-cell lymphoma, follicular lymphoma, etc. In compounds of formula (I)

.

W is O; X is NH, O, SO or SO₂; Y denotes a hydrogen atom, halogen atom, C_1-6alkyl or C_1-6alkoxy, each of A and B independently denotes a hydrogen atom, halogen atom or di(C_1-6alkyl)aminomethyl; Z is selected from a group consisting of formulae Z2, Z4, Z28, Z61, Z100, Z113, Z138, Z164, Z168 and Z189 .

EFFECT: treating different diseases.

10 cl, 3 dwg, 19 tbl, 237 ex